China Biotech Weekly #8: WuXi AppTec Earnings — Revenue Up, BIOSECURE Risk Priced In
WuXi AppTec reported Q4 2025 earnings showing continued US client revenue growth despite BIOSECURE uncertainty. We analyze what the numbers reveal about client retention, the XDC IPO timeline, and what the brief 1260H listing means for your compliance planning.